Compare Viatris Inc (VTRS) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Vanguard Growth Index Fund ETF — how do they compare? Viatris Inc trades at $16.19 (market cap $18.49B), while Vanguard Growth Index Fund ETF trades at $89.72. The key difference: Viatris Inc pays a 2.98% dividend while Vanguard Growth Index Fund ETF pays none, and Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Viatris Inc nearer its low. Which is the better fit depends on your goals.
| VTRS | VUG | |
|---|---|---|
Market Cap | $18.49B | — |
Sector | Health | Sector/Thematic |
52-Week High | $17.86 | $90.29 |
52-Week Low | $9.49 | $70.00 |
Enterprise Value | $30.61B | — |
Dividend Yield | 2.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Vanguard Growth ETF (VUG) trades at $88.87, down 0.35% today, with a bullish technical outlook supported by moving averages. The ETF shows strong institutional accumulation, with multiple firms increasing positions by over 500% in Q2 2026. Technical indicators show overbought RSI levels but strong trend momentum with ADX readings above 30.
VUG offers exposure to large-cap growth stocks with historical outperformance versus the S&P 500. Risks include growth stock volatility and concentration in technology sectors. The ETF remains attractive for long-term investors seeking growth exposure, though current overbought conditions suggest potential for near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
